Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Real-World Evidence in Type 2 Diabetes: Focus on SGLT2 inhibitors and GLP-1 Receptor Agonists

A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes

ByHuan Huang, PhD,Kelly F. Bell, PharmD, MSPhr,Ray Gani, PhD,Cathy W. Tugwell, RN, BSN,James M. Eudicone, MS, MBA,Michelle R. Krukas-Hampel, MA

April 14th 2018

Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Trials: Implications for the General Type 2 Diabetes US Population

ByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Kelly F. Bell, PharmD, MSPhr,Devin M. Enhoffer, PharmD,Keith Latham, PharmD,Jennifer B. Green, MD

April 14th 2018

Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population

ByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Kelly F. Bell, PharmD, MSPhr,Devin M. Enhoffer, PharmD,Keith Latham, PharmD,Jennifer B. Green, MD

April 14th 2018

Comparison of Low-Dose Liraglutide Use Versus Other GLP-1 Receptor Agonists in Patients Without Type 2 Diabetes

ByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Sepehr Farahbakhshian, MS,Carrie McAdam-Marx, PhD, MSCI, RPh

April 14th 2018

Real World Evidence in Type 2 Diabetes: Focus on SGLT2 Inhibitors and GLP-1 Receptor Agonist Participating Faculty

By

April 14th 2018

Trending on AJMC

Iron Dysregulation Linked to MS Progression, Review Finds

Metabolic Issues More Common in Patients With HIV

Efficacy of Ruxolitinib Cream in Nonsegmental Vitiligo Confirmed in Real-World Study

West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations

Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

© 2025 MJH Life Sciences^®

All rights reserved.